NEW YORK, Feb. 26 - Paradigm Genetics and VDDI Pharmaceuticals will research and develop novel antibiotics for certain bacteria that may be used as bioterror agents, the companies said on Tuesday.

Terms of the deal call for Paradigm to supply its MetaVantage platform. VDDI, meanwhile, will provide samples of a new class of antimicrobials recently discovered at the University of Alabama.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers in China have generated mouse pups from same-sex parents, according to Scientific American.

Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.

The South China Morning Post reports that Hong Kong plans to add HK$20 billion (US$2.6 billion) to a research endowment.

In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.